Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences

Business Wire September 15, 2021

Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Business Wire September 10, 2021

Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases

Business Wire August 17, 2021

Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference

Business Wire August 9, 2021

Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights

Business Wire August 5, 2021

Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021

Business Wire July 26, 2021

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

PR Newswire July 23, 2021

Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange

Business Wire July 16, 2021

Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs

Business Wire June 30, 2021

Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)

Business Wire June 25, 2021

Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors

Business Wire June 14, 2021

Aurinia Announces Results of the 2021 Annual General Meeting

Business Wire June 7, 2021

Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress

Business Wire June 7, 2021

Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Business Wire May 27, 2021

Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS(TM) (voclosporin) in Subjects with Lupus Nephritis

Business Wire May 20, 2021

Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Business Wire May 14, 2021

Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis

Business Wire May 10, 2021

Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS(TM) (voclosporin) in The Lancet

Business Wire May 10, 2021

Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights

Business Wire May 6, 2021

Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021

Business Wire April 28, 2021